Self-Administered Drug Exclusion List (SAD List)

Updated monthly
Contractor
WPS (A52800)
Last updated
September 6, 2026
Excluded entries
151
HCPCS codes
58
Source
CMS

The full list

Excluded CPT/HCPCS codes

Our full list of 151 excluded entries from WPS Insurance Corporation's CMS self-administered drug exclusion list (article A52800), last refreshed September 6, 2026. Search, sort, or export the list, which may change and could contain errors.

  • J3490 41 entries Unclassified drugs
  • J3590 33 entries Unclassified biologics
  • C9399 20 entries Unclassified drugs or biologicals

These three unclassified-drug codes account for 94 of the 151 excluded entries; the remainder are specific J-codes for individual products.

CodeDescriptor Generic NameDescriptor Brand NameExclusion Effective DateExclusion End DateReason for Exclusion
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSAdalimumab-aacf (Idacio®), Adalimumab-afzb (Abrilada™), Adalimumab-bwwd (Hadlima), Adalimumab-fkjp (Hulio®), Adalimumab-adaz (Hyrimoz), Adalimumab-aqvh (Yusimry)6/25/23N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSadalimumab-aaty (Yuflyma®)1/14/24N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSAll insulin products12/11/22N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSbimekizumab-bkzx (Bimzelx®)8/29/26N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSLiraglutide (Saxenda®)6/15/16N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSLiraglutide (Victoza®)10/16/11N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSNemolizumab-ilto (Nemluvio)6/14/26N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSofatumumab (Kesimpta®) subcutaneous use*7/24/22N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSPasireotide (Signifor®)11/15/21N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSRebif® (Interferon Beta–1A, 1 mcg)7/16/17N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSRisankizumab-rzaa (Skyrizi™) subcutaneous use1/12/20N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSsecukinumab (Cosentyx™)6/15/15N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSSemaglutide (Ozempic®)4/1/24N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSSemaglutide (Wegovy®)6/30/24N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSSogroya® (somapacitan-beco)11/15/21N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSTesamorelin (Egrifta™)7/16/17N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALStirzepatide (Mounjaro™)12/11/22N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSTirzepatide (Zepbound™)6/30/24N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALStralokinumab-idrm (Adbry™)11/13/22N/AApparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSVedolizumab (Entyvio®) subcutaneous use*1/14/24N/AApparent on its Face
J0129INJECTION, ABATACEPT, 10 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED)Orencia® subcutaneous use*4/1/21N/AApparent on its Face
J0139INJECTION, ADALIMUMAB, 1 MGHumira®1/1/25N/AApparent on its Face
J0270INJECTION, ALPROSTADIL, 1.25 MCG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED)Caverject, Edex2/1/08N/AApparent on its Face
J0364INJECTION, APOMORPHINE HYDROCHLORIDE, 1 MGApokyn®4/1/21N/AApparent on its Face
J0490INJECTION, BELIMUMAB, 10 MGBenlysta®, subcutaneous use*4/1/21N/AApparent on its Face
J0593INJECTION, LANADELUMAB-FLYO, 1 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF-ADMINISTERED)Takhzyro®12/2/19N/AApparent on its Face
J0599INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), (HAEGARDA), 10 UNITSHaegarda®1/1/19N/AApparent on its Face
J0630INJECTION, CALCITONIN SALMON, UP TO 400 UNITSCalcimar, Miacalcin2/1/08N/AApparent on its Face
J0801INJECTION, CORTICOTROPIN (ACTHAR GEL), UP TO 40 UNITSH.P. Acthar® Gel subcutaneous use**10/1/23N/AApparent on its Face
J0802INJECTION, CORTICOTROPIN (ANI), UP TO 40 UNITSPurified Cortrophin Gel® subcutaneous use**10/1/23N/AApparent on its Face
J1324INJECTION, ENFUVIRTIDE, 1 MGFuzeon2/1/08N/AApparent on its Face
J1438INJECTION, ETANERCEPT, 25 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED)Enbrel2/1/08N/AApparent on its Face
J1595INJECTION, GLATIRAMER ACETATE, 20 MGCopaxone™2/1/08N/AApparent on its Face
J1628INJECTION, GUSELKUMAB, 1 MGTremfya® (guselkumab)*4/1/21N/AApparent on its Face
J1675INJECTION, HISTRELIN ACETATE, 10 MICROGRAMSSupprelin LA™2/1/08N/AApparent on its Face
J1744INJECTION, ICATIBANT, 1 MGFirazyr™11/15/11N/AApparent on its Face
J1748INJECTION, INFLIXIMAB-DYYB (ZYMFENTRA), 10 MGInfliximab-dyyb (Zymfentra)8/18/24N/AApparent on its Face
J1811INSULIN (FIASP) FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP) PER 50 UNITSFiasp® for insulin pump use9/3/23N/AApparent on its Face
J1812INSULIN (FIASP), PER 5 UNITSFiasp® injection*9/3/23N/AApparent on its Face
J1813INSULIN (LYUMJEV) FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP) PER 50 UNITSLyumjev® for insulin pump use9/3/23N/AApparent on its Face
J1814INSULIN (LYUMJEV), PER 5 UNITSLyumjev® injection*9/3/23N/AApparent on its Face
J1815INJECTION, INSULIN, PER 5 UNITSAll insulin products12/11/22N/AApparent on its Face
J1815INJECTION, INSULIN, PER 5 UNITSHumalog, Humulin, Iletin, Insulin Lispro, Novo Nordisk, NPH, Pork Insulin, Regular Insulin, Ultralente, Velosulin, Humulin R, Iletin II Regular Port, Insulin Purified Pork, ReliOn, Lente Iletin I, Novolin R, Humulin R U-5002/1/08N/AApparent on its Face
J1817INSULIN FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP) PER 50 UNITSAll insulin products12/11/22N/AApparent on its Face
J1817INSULIN FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP) PER 50 UNITSHumalog, Humulin, Vesolin BR, Iletin II NPH Pork, Lantus, Lispro-PFC, Novolin, Novolog, Novolog Flexpen, Novolog Mix, ReliOn Novolin2/1/08N/AApparent on its Face
J1826INJECTION, INTERFERON BETA-1A, 30 MCGAvonex Pen®, Rebif®, Rebif® Rebidose®11/15/21N/AApparent on its Face
J1830INJECTION, INTERFERON BETA-1B, 0.25 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED)Betaseron™2/1/08N/AApparent on its Face
J1941INJECTION, FUROSEMIDE (FUROSCIX), 20 MGFuroscix®9/3/23N/AApparent on its Face
J2170INJECTION, MECASERMIN, 1 MGIplex™ Increlex™2/1/08N/AApparent on its Face
J2212INJECTION, METHYLNALTREXONE, 0.1 MGRelistor™2/15/13N/AApparent on its Face
J2267INJECTION, MIRIKIZUMAB-MRKZ, 1 MGmirikizumab-mrkz (Omvoh™) subcutaneous use*7/1/24N/AApparent on its Face
J2354INJECTION, OCTREOTIDE, NON-DEPOT FORM FOR SUBCUTANEOUS OR INTRAVENOUS INJECTION, 25 MCGSandostatin™, subcutaneous use*2/1/08N/AApparent on its Face
J2440INJECTION, PAPAVERINE HCL, UP TO 60 MGPapaverine HCL2/1/08N/AApparent on its Face
J2941INJECTION, SOMATROPIN, 1 MGGenotropin™2/1/08N/AApparent on its Face
J3030INJECTION, SUMATRIPTAN SUCCINATE, 6 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED)Imitrex™2/1/08N/AApparent on its Face
J3031INJECTION, FREMANEZUMAB-VFRM, 1 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF-ADMINISTERED)Ajovy™4/1/21N/AApparent on its Face
J3110INJECTION, TERIPARATIDE, 10 MCGForteo™2/1/08N/AApparent on its Face
J3357USTEKINUMAB, FOR SUBCUTANEOUS INJECTION, 1 MGStelara®11/15/21N/AApparent on its Face
J3490UNCLASSIFIED DRUGSAbaloparatide (Tymlos™)7/16/18N/AApparent on its Face
J3490UNCLASSIFIED DRUGSAdalimumab-aacf (Idacio®), Adalimumab-afzb (Abrilada™), Adalimumab-bwwd (Hadlima), Adalimumab-fkjp (Hulio®), Adalimumab-adaz (Hyrimoz), Adalimumab-aqvh (Yusimry)6/25/23N/AApparent on its Face
J3490UNCLASSIFIED DRUGSadalimumab-aaty (Yuflyma®)1/14/24N/AApparent on its Face
J3490UNCLASSIFIED DRUGSAdalimumab-atto (AMJEVITA™)2/15/17N/AApparent on its Face
J3490UNCLASSIFIED DRUGSAlbiglutide (Tanzeum™)6/15/16N/AApparent on its Face
J3490UNCLASSIFIED DRUGSAlirocumab (Praulent™)6/15/16N/AApparent on its Face
J3490UNCLASSIFIED DRUGSAll insulin products12/11/22N/AApparent on its Face
J3490UNCLASSIFIED DRUGSbimekizumab-bkzx (Bimzelx®)8/29/26N/AApparent on its Face
J3490UNCLASSIFIED DRUGSDulaglutide (Trulicity™)6/15/16N/AApparent on its Face
J3490UNCLASSIFIED DRUGSetanercept-szzs (Erelzi)11/15/16N/AApparent on its Face
J3490UNCLASSIFIED DRUGSEvolocumab (Repatha™)6/15/16N/AApparent on its Face
J3490UNCLASSIFIED DRUGSGolimumab (SIMPONI)2/15/17N/AApparent on its Face
J3490UNCLASSIFIED DRUGSInjection lebrikizumab-lbkz; biosimilar (Ebglyss®)4/17/25N/AApparent on its Face
J3490UNCLASSIFIED DRUGSInjection, ustekinumab-stba (Steqeyma); Biosimilar (SteQeyma®) subcutaneous use*4/17/25N/AApparent on its Face
J3490UNCLASSIFIED DRUGSInsulin Glargine (Lantus SoloStar™)6/15/16N/AApparent on its Face
J3490UNCLASSIFIED DRUGSInsulin Glargine (Toujeo SoloStar™)6/15/16N/AApparent on its Face
J3490UNCLASSIFIED DRUGSIxekizumab (Taltz™)6/15/16N/AApparent on its Face
J3490UNCLASSIFIED DRUGSLiraglutide (Saxenda™)6/15/16N/AApparent on its Face
J3490UNCLASSIFIED DRUGSLiraglutide (Victoza™)10/16/11N/AApparent on its Face
J3490UNCLASSIFIED DRUGSMethotrexate (Otrexup™)6/15/16N/AApparent on its Face
J3490UNCLASSIFIED DRUGSMethotrexate (Rasuvo™)6/15/16N/AApparent on its Face
J3490UNCLASSIFIED DRUGSMetreleptin (Myalept™)6/15/16N/AApparent on its Face
J3490UNCLASSIFIED DRUGSMipomersen sodium (Kynamro™)9/15/13N/AApparent on its Face
J3490UNCLASSIFIED DRUGSNemolizumab-ilto (Nemluvio)6/14/26N/AApparent on its Face
J3490UNCLASSIFIED DRUGSofatumumab (Kesimpta®) subcutaneous use*7/24/22N/AApparent on its Face
J3490UNCLASSIFIED DRUGSParathyroid hormone (Natpara™)6/15/16N/AApparent on its Face
J3490UNCLASSIFIED DRUGSPasireotide (Signifor™)6/15/16N/AApparent on its Face
J3490UNCLASSIFIED DRUGSPeginterferon beta-1a (Plegridy™)6/15/16N/AApparent on its Face
J3490UNCLASSIFIED DRUGSPramlintide (Symlin™)2/1/08N/AApparent on its Face
J3490UNCLASSIFIED DRUGSQuadmix (+ Atropine)7/16/17N/AApparent on its Face
J3490UNCLASSIFIED DRUGSRebif® (Interferon Beta–1A, 1 mcg)7/16/17N/AApparent on its Face
J3490UNCLASSIFIED DRUGSRisankizumab-rzaa (Skyrizi™) subcutaneous use1/12/20N/AApparent on its Face
J3490UNCLASSIFIED DRUGSSarilumab (Kevzara™)4/1/21N/AApparent on its Face
J3490UNCLASSIFIED DRUGSsecukinumab (Cosentyx™)6/15/15N/AApparent on its Face
J3490UNCLASSIFIED DRUGSSogroya® (somapacitan-beco)11/15/21N/AApparent on its Face
J3490UNCLASSIFIED DRUGSTesamorelin (Egrifta™)10/16/11N/AApparent on its Face
J3490UNCLASSIFIED DRUGStirzepatide (Mounjaro™)12/11/22N/AApparent on its Face
J3490UNCLASSIFIED DRUGSTirzepatide (Zepbound™)6/30/24N/AApparent on its Face
J3490UNCLASSIFIED DRUGStralokinumab-idrm (Adbry™)11/13/22N/AApparent on its Face
J3490UNCLASSIFIED DRUGSTriMix™10/16/11N/AApparent on its Face
J3490UNCLASSIFIED DRUGSVedolizumab (Entyvio®) subcutaneous use*1/14/24N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSAdalimumab-aacf (Idacio®), Adalimumab-afzb (Abrilada™), Adalimumab-bwwd (Hadlima), Adalimumab-fkjp (Hulio®), Adalimumab-adaz (Hyrimoz), Adalimumab-aqvh (Yusimry)6/25/23N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSadalimumab-aaty (Yuflyma®)1/14/24N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSadalimumab-adbm (Cyltezo™ )4/1/21N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSAll insulin products12/11/22N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSAnakinra (Kineret™)2/1/08N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSAsfotase-alfa (Strensiq®)4/1/21N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSbimekizumab-bkzx (Bimzelx®)8/29/26N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSBrodalumab (Siliq)7/16/17N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSDupilumab (Dupixent)7/16/17N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSerenumab-aooe (Aimovig™)4/1/21N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSExenatide (Bydureon™)6/15/16N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSExenatide, (Byetta™)10/16/08N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSGalcenezumab-gnlm (Emgality™)4/1/21N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSInjection lebrikizumab-lbkz; biosimilar (Ebglyss®)4/17/25N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSInjection, ustekinumab-stba (Steqeyma); Biosimilar (SteQeyma®) subcutaneous use*4/17/25N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSLiraglutide (Saxenda®)6/15/16N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSLiraglutide (Victoza®)10/16/11N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSNemolizumab-ilto (Nemluvio)6/14/26N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSofatumumab (Kesimpta®) subcutaneous use*7/24/22N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSPeginterferon alfa-2b, (Pegintron™ Sylatron™)2/1/08N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSPegvisomant, (Somavert™)2/1/08N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSRebif® (Interferon Beta–1A, 1 mcg)7/16/17N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSRisankizumab-rzaa (Skyrizi™) subcutaneous use1/12/20N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSRopeginterferon alfa-2b-njft (BESREMI®)4/24/22N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSSarilumab (Kevzara®)4/1/21N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSsecukinumab (Cosentyx™)6/15/15N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSSemaglutide (Ozempic®)4/1/21N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSSemaglutide (Wegovy®)6/30/24N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSSogroya® (somapacitan-beco)11/15/21N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICStirzepatide (Mounjaro™)12/11/22N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSTirzepatide (Zepbound™)6/30/24N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICStralokinumab-idrm (Adbry™)11/13/22N/AApparent on its Face
J3590UNCLASSIFIED BIOLOGICSVedolizumab (Entyvio®) subcutaneous use*1/14/24N/AApparent on its Face
J9213INJECTION, INTERFERON, ALFA-2A, RECOMBINANT, 3 MILLION UNITSPeginterferon alfa-2a, (Pegasys®, Pegasys® Proclick™)2/15/13N/AApparent on its Face
J9216INJECTION, INTERFERON, GAMMA 1-B, 3 MILLION UNITSActimmune™2/1/08N/AApparent on its Face
J9218LEUPROLIDE ACETATE, PER 1 MGLupron™2/1/08N/AApparent on its Face
Q3027INJECTION, INTERFERON BETA-1A, 1 MCG FOR INTRAMUSCULAR USEAvonex™1/1/14N/AApparent on its Face
Q3028INJECTION, INTERFERON BETA-1A, 1 MCG FOR SUBCUTANEOUS USERebif™1/1/14N/AApparent on its Face
Q5098INJECTION, USTEKINUMAB-SRLF (IMULDOSA), BIOSIMILAR, 1 MGImuldosa™ subcutaneous use*7/1/25N/AApparent on its Face
Q5099INJECTION, USTEKINUMAB-STBA (STEQEYMA), BIOSIMILAR, 1 MGSteqeyma® subcutaneous use*7/1/25N/AApparent on its Face
Q5100INJECTION, USTEKINUMAB-KFCE (YESINTEK), BIOSIMILAR, 1 MGYesintek™ subcutaneous use*7/1/25N/AApparent on its Face
Q5137INJECTION, USTEKINUMAB-AUUB (WEZLANA), BIOSIMILAR, SUBCUTANEOUS, 1 MGustekinumab-auub (Wezlana™) subcutaneous use*7/1/24N/AApparent on its Face
Q5140INJECTION, ADALIMUMAB-FKJP, BIOSIMILAR, 1 MGHulio®1/1/25N/AApparent on its Face
Q5141INJECTION, ADALIMUMAB-AATY, BIOSIMILAR, 1 MGYuflyma®1/1/25N/AApparent on its Face
Q5142INJECTION, ADALIMUMAB-RYVK BIOSIMILAR, 1 MGSimlandi®1/1/25N/AApparent on its Face
Q5143INJECTION, ADALIMUMAB-ADBM, BIOSIMILAR, 1 MGCyltezo®1/1/25N/AApparent on its Face
Q5144INJECTION, ADALIMUMAB-AACF (IDACIO), BIOSIMILAR, 1 MGIdacio®1/1/25N/AApparent on its Face
Q5145INJECTION, ADALIMUMAB-AFZB (ABRILADA), BIOSIMILAR, 1 MGAbrilada®1/1/25N/AApparent on its Face
Q5164INJECTION, USTEKINUMAB-HMNY (STARJEMZA), BIOSIMILAR, 1 MGStarjemza™ subcutaneous use*8/29/26N/AApparent on its Face
Q9996INJECTION, USTEKINUMAB-TTWE (PYZCHIVA), SUBCUTANEOUS, 1 MGPyzchiva1/1/25N/AApparent on its Face
Q9998INJECTION, USTEKINUMAB-AEKN (SELARSDI), BIOSIMILAR, 1 MGSelarsdi™ subcutaneous use*1/1/25N/AApparent on its Face
Q9999INJECTION, USTEKINUMAB-AAUZ (OTULFI), BIOSIMILAR, 1 MGOtulfi® subcutaneous use*4/1/25N/AApparent on its Face

Exclusion ended

Non-excluded (ended) codes

13 CPT/HCPCS codes whose exclusion carries an end date. As of that date the exclusion no longer applies, so the code is no longer treated as self-administered for Part B purposes.

CodeDescriptor Generic NameDescriptor Brand NameExclusion Effective DateExclusion End DateReason for Exclusion
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSmirikizumab-mrkz (Omvoh™) subcutaneous use*1/14/247/1/24Apparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALStezepelumab-ekko (Tezspire™)7/10/227/10/22Apparent on its Face
C9399UNCLASSIFIED DRUGS OR BIOLOGICALSustekinumab-auub (Wezlana™) subcutaneous use*3/16/247/1/24Apparent on its Face
J0129INJECTION, ABATACEPT, 10 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED)Orencia11/15/1311/15/13
J1559INJECTION, IMMUNE GLOBULIN (HIZENTRA), 100 MGHizentra1/15/111/1/21Apparent on its Face
J1814INSULIN (LYUMJEV), PER 5 UNITSLyumjev® 200 IU9/3/239/3/23Apparent on its Face
J3357USTEKINUMAB, FOR SUBCUTANEOUS INJECTION, 1 MGStelara™9/15/136/1/14
J3490UNCLASSIFIED DRUGSmirikizumab-mrkz (Omvoh™) subcutaneous use*1/14/247/1/24Apparent on its Face
J3490UNCLASSIFIED DRUGStezepelumab-ekko (Tezspire™)7/10/227/10/22Apparent on its Face
J3490UNCLASSIFIED DRUGSustekinumab-auub (Wezlana™) subcutaneous use*3/16/247/1/24Apparent on its Face
J3590UNCLASSIFIED BIOLOGICSmirikizumab-mrkz (Omvoh™) subcutaneous use*1/14/247/1/24Apparent on its Face
J3590UNCLASSIFIED BIOLOGICStezepelumab-ekko (Tezspire™)7/10/227/10/22Apparent on its Face
J3590UNCLASSIFIED BIOLOGICSustekinumab-auub (Wezlana™) subcutaneous use*3/16/247/1/24Apparent on its Face

Overview

What is the SAD exclusion list?

The CMS self-administered drug exclusion list contains drugs that are usually self-administered by the patient and, therefore, are not typically covered by Medicare Part B when administered by a physician, whether in a physician's office or a hospital outpatient department. This is because Medicare Part B generally does not cover the cost of self-administered drugs that beneficiaries would typically take on their own.

Each Medicare Administrative Contractor (MAC) maintains its own exclusion list, and CMS refreshes the underlying data quarterly. BuyandBill.com republishes each MAC's self-administered drug exclusion list from the CMS Coverage API so providers can check a code before billing.

How it is decided

How CMS decides a drug is self-administered

A drug lands on the exclusion list when CMS determines it is usually administered by the patient. Four factors drive that determination.

  • Usually self-administered

    CMS excludes a drug when it is self-administered more than 50% of the time across all Medicare beneficiaries who use it, a population-level determination rather than a single claim.

  • Route of administration

    Products a patient can reasonably give themselves, such as subcutaneous injections or oral therapies, are far more likely to be excluded than infusions that require clinical administration.

  • Apparent on its face

    Some products are excluded because they are plainly intended for patient self-administration. This is the determination method recorded for the entries on this list.

  • Acute vs. chronic use

    CMS weighs whether a drug treats an acute condition, more often given in the office, or a chronic one the patient manages at home over an extended course of therapy.

FAQ

Frequently asked questions

What is the self-administered drug (SAD) exclusion list?

The SAD exclusion list is a CMS list of drugs that are usually self-administered by the patient and are therefore not typically covered by Medicare Part B when administered by a physician, whether in a physician's office or a hospital outpatient setting. Each Medicare Administrative Contractor (MAC) publishes its own exclusion list; BuyandBill.com republishes the list in conjunction with the CMS data file.

Why does Medicare Part B not cover these drugs?

Medicare Part B generally covers drugs that are administered by a physician or under direct supervision and that are not usually self-administered. When a drug is usually self-administered, the cost is expected to fall under Part D or the patient rather than Part B.

What does "Apparent on its Face" mean?

It is one of the methods CMS uses to determine that a drug is self-administered. The product is excluded because it is clearly intended for the patient to administer themselves.

How often is the SAD list updated?

CMS updates the self-administered drug exclusion data on a quarterly basis. BuyandBill.com refreshes the list monthly from the CMS Coverage API so it reflects the current version of each contractor’s article.

What is the difference between the excluded and the non-excluded (ended) list?

The excluded list contains codes currently treated as self-administered and not covered by Part B in the outpatient setting. The non-excluded list contains codes whose exclusion has an end date, meaning the exclusion no longer applies as of that date.

How does the SAD list affect buy and bill?

If an office-administered drug appears on the exclusion list, a Part B claim in the outpatient setting may be denied as self-administered. Checking the list before billing helps providers avoid denials and route the claim correctly.

Check whether a drug is payable under Part B →